Business Wire

CA-DENODO

22.5.2024 13:01:32 CEST | Business Wire | Press release

Share
Denodo Redoubles Focus on Energy and Utilities

Denodo, a leader in data management, announced that the company is expanding its efforts to provide energy and utility companies with the necessary data management capabilities to gain advanced capabilities and meet new renewable energy requirements, all while remaining in compliance with increasingly stringent regulatory demands.

Facing numerous challenges, including generating, managing, and consuming new, decarbonized and increasingly digitized sources of energy; maintaining resilience and sustainability in a time of change; developing new technologies such as virtual power plants (VPPs) based on intelligent operations; all while managing a rising number of environmental, social, and governance (ESG) and sustainability initiatives; energy and utility companies need to be able to manage data so that it helps to overcome these challenges, rather than adding to them.

The Denodo Platform facilitates this by providing real-time access to data across myriad distributed energy resources, while enabling the establishment of a unified semantic layer over all data sources, to deliver data when it is needed, in the language required by each data consumer. This provides energy and utility companies with the foundation to overcome myriad known and unknown challenges. The Denodo Platform enables such capabilities as continuous monitoring and control, and makes it possible for VPP operators to make fast, informed decisions in response to changes in energy demand, pricing, and environmental conditions. By enabling such capabilities, the Denodo Platform provides energy and utility companies with a reliable foundation for innovation.

Denodo has a strong heritage in providing impactful data management solutions to energy and utility companies, such as VTTI, a Netherlands-based energy storage and developer of critical energy infrastructure; BHP, a global resources company headquartered in Melbourne, Australia; Engie Mexico, an energy company that is committed to bringing energy to the people of Mexico; and Suez, a French multinational corporation with operations in water, electricity, natural gas supply, and waste management.

Hans Geurts, chief information officer for VTTI, says, “As a rapidly growing organization in an uncertain geopolitical environment, laying a strong data foundation was critical for us to become data-driven. The Denodo Platform has helped us in simplifying and standardizing our data infrastructure, while boosting our business resilience.” The Denodo Platform acts as VTTI’s single source of truth for enterprise resource planning (ERP) data. The company leverages it to synthesize, combine, and analyze operational insights to improve ways of working and address inefficiencies in the operational micro-steps at the company’s terminals. It also helps VTTI to visualize and understand product trade flows through the terminals and various modes of transport, helping VTTI’s commercial teams to better serve customers.

Joshua Fletcher, superintendent HSE, Reporting at BHP, made similar statements about the effect that the Denodo Platform had on the company’s business. “The Denodo Platform helps us to reduce the overall size of the data sets that need to be moved over the network. It helped us to create a logical data fabric that makes our data assets reusable and can be consumed by users spread across the globe.”

Luis Guadarrama, senior manager, Data Analytics and Innovation at Engie Mexico, says, “The Denodo Platform delivers data quickly and easily, which helps us to deliver value to the business and democratize data access. Our business users might not understand the technical part, but they do understand that there’s something called ‘the Denodo Platform’ that helps them to connect to data in an easier way, to make better decisions.” Engie Mexico leveraged the Denodo Platform to enable a variety of strategic initiatives, including web services that help hundreds of thousands of customers to balance their use of natural gas, chatbots that assist in problem resolution, and machine learning (ML) algorithms that analyze the behavior patterns of business-to-consumer gas customers.

Denodo believes that VPPs are the power plants of the future. VPPs can run energy in the cloud, and they can supply renewable energy on-demand, through innovative web-based interfaces that can remotely link and manage homes with solar and battery storage. Additionally, VPPs can feed power back to the grid during peak times, to relieve the load and keep the network stable.

Denodo also believes that data-driven, intelligent operations is a critical capability that can greatly assist utility CIOs in designing fit-for-the-future assets that bridge physical and digital phenomena. The Denodo Platform facilitates the development of intelligent operations and VPPs through diverse capabilities, including distributed energy resource management, predictive analytics for maintenance, and optimization of energy assets.

“Advanced data management technology will be essential in enabling new capabilities that oil and gas companies need to thrive, both now and beyond the energy transition,” said Paul Moxon, SVP Data Architecture and Chief Evangelist at Denodo. “Power plants of the future will operate in an eco-centric, distributed manner, enabling the data-driven, intelligent VPPs of the future. The Denodo Platform, with its ability to provide real-time data access to increasingly diverse data sources, will underpin success by providing energy and utility business users with access to data at the speed of business.”

For more information:

About Denodo

Denodo is a leader in data management. The award-winning Denodo Platform is the leading logical data management platform for delivering data in the language of business, at the speed of business, for all data-related initiatives across the organization. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across enterprises in 30+ industries all over the world have received payback in less than six months. For more information, visit denodo.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522149387/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye